Evidence has accumulated, both in experimental models [20-23] and clinical studies [24-29], in a broad variety of vascular beds and organs, that reducing the RAS activation, either with ACE inhibitors or ARBs, reduces inflammation, improves endothelial dysfunction caused by hypertension and/or diabetes, recouples eNOS and restores NO availability. The gene discussed is ACE; the disease is diabetes mellitus.